PROCEPT BioRobotics Corporation Common Stock (PRCT) Stock
Key stats
- Market cap
- $1.34B
- Price / Earnings ratio
- -11.5x
- EPS (TTM)
- -$2.02
- Volume
- Loading
- 52-week high
- $38.11
- 52-week low
- $16.67
Source: third-party data provider, as of November 13, 2026
Compare with PRCT
Recent news

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
PRCT

PRCT Deadline: Rosen Law Firm Urges PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
PRCT Deadline: Rosen Law Firm Urges PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
PRCT

PROCEPT 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against PROCEPT BioRobotics Corporation - PRCT
PROCEPT 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against PROCEPT BioRobotics Corporation - PRCT
PRCT

PRCT ALERT: Hagens Berman Reminds PROCEPT BioRobotics (PRCT) Investors of the September 22, 2026 Lead Plaintiff Deadline
PRCT ALERT: Hagens Berman Reminds PROCEPT BioRobotics (PRCT) Investors of the September 22, 2026 Lead Plaintiff Deadline
PRCT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 67.38
- MACD 12/26/9
- 0.94
- EMA 9 of MACD
- 0.55
- MACD histogram
- 0.39
- SMA 50
- $19.44
- Price above SMA 50
- EMA 50
- $19.95
- Price above EMA 50
- SMA 200
- $22.96
- Price above SMA 200
- EMA 200
- $23.51
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
PRCT

PRCT Deadline: Rosen Law Firm Urges PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
PRCT Deadline: Rosen Law Firm Urges PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
PRCT

PROCEPT 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against PROCEPT BioRobotics Corporation - PRCT
PROCEPT 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against PROCEPT BioRobotics Corporation - PRCT
PRCT

PRCT ALERT: Hagens Berman Reminds PROCEPT BioRobotics (PRCT) Investors of the September 22, 2026 Lead Plaintiff Deadline
PRCT ALERT: Hagens Berman Reminds PROCEPT BioRobotics (PRCT) Investors of the September 22, 2026 Lead Plaintiff Deadline
PRCT

LAWSUIT ALERT: Investors who lost money with PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares should contact the Shareholders Foundation
LAWSUIT ALERT: Investors who lost money with PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares should contact the Shareholders Foundation
PRCT

PRCT Shareholder Alert: September 22, 2026 Lead Plaintiff Deadline in PROCEPT BIOROBOTICS CORPORATION Securities Class Action - Contact Levi & Korsinsky
PRCT Shareholder Alert: September 22, 2026 Lead Plaintiff Deadline in PROCEPT BIOROBOTICS CORPORATION Securities Class Action - Contact Levi & Korsinsky
PRCT

PRCT INVESTOR REMINDER: PROCEPT BioRobotics Corporation Investors Have Until September 22, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role
PRCT INVESTOR REMINDER: PROCEPT BioRobotics Corporation Investors Have Until September 22, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role
PRCT

Procept BioRobotics CEO Buys 23,900 Shares Amid 48% Stock Decline. What Does This Tell Investors?
Procept BioRobotics CEO Buys 23,900 Shares Amid 48% Stock Decline. What Does This Tell Investors?
PRCT

Robbins LLP Encourages PRCT Shareholders With Significant Losses to Contact the Firm for Information About the Class Action Against PROCEPT BioRobotics Corporation
Robbins LLP Encourages PRCT Shareholders With Significant Losses to Contact the Firm for Information About the Class Action Against PROCEPT BioRobotics Corporation
PRCT

PRCT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against PROCEPT BioRobotics Corporation and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit
PRCT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against PROCEPT BioRobotics Corporation and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit
PRCT
News tone: automated (AI) classification of the article's content, not a price prediction.
About PROCEPT BioRobotics Corporation Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Larry L. Wood | President, CEO & Director | 1966 |
| Mr. Kevin Waters | Executive VP & CFO | 1977 |
| Ms. Alaleh Nouri | EVP, Chief Legal Officer & Corporate Secretary | 1979 |
| Mr. Christofer Christoforou | Executive Vice President of Operations | 1970 |
| Mr. Barry Templin | Executive VP & CTO | — |
| Mr. Matthew James Bacso C.F.A. | Vice President of Investor Relations | — |
| Ms. Pooja Sharma Rao | Executive VP and Chief Strategy & Marketing Officer | — |
| Ms. Stacey L. Porter | Executive VP & Chief People Officer | 1975 |
| Mr. Bijesh Chandran | Executive Vice President of Regulatory Affairs & Quality Assurance | — |
| Mr. Stephen J. McGill | Senior VP & GM of International | 1962 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 67.38
- MACD 12/26/9
- 0.94
- EMA 9 of MACD
- 0.55
- MACD histogram
- 0.39
- SMA 50
- $19.44
- Price above SMA 50
- EMA 50
- $19.95
- Price above EMA 50
- SMA 200
- $22.96
- Price above SMA 200
- EMA 200
- $23.51
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $21.00
- Average
- $24.25
- High
- $30.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -22.4 | -26.1 | ||||||||||
| 2022 | -26.9 | +31.8 | +34.4 | +0.3 | +5.5 | -18.7 | +22.2 | +6.0 | +2.7 | +7.1 | -6.9 | -9.5 |
| 2023 | -1.7 | -4.3 | -24.9 | -4.0 | +6.9 | +8.8 | -2.9 | +0.6 | -4.0 | -15.3 | +34.6 | +12.2 |
| 2024 | +11.7 | +2.0 | +0.7 | +12.7 | +9.6 | -6.8 | +2.3 | +27.4 | +6.7 | +18.1 | +3.6 | -16.2 |
| 2025 | -12.8 | -9.7 | -3.9 | -5.4 | +9.7 | -0.6 | -14.2 | -19.6 | -9.8 | -2.0 | -8.2 | +3.5 |
| 2026 | -5.9 | -22.1 | -3.4 | -5.2 | +6.9 | -19.0 | -20.7 | +15.3 | -12.9 | +12.8 | +18.6 |



